BioAge starts mid-stage trial for oral drug targeting heart disease risk (opens in new tab)

BioAge Labs has dosed the first participant in QUELL-CV, a randomized, double-blind, placebo-controlled, dose-ranging Phase 2 proof-of-concept trial evaluating BGE-102 in approximately 160 adults at elevated cardiovascular risk. The 12-week trial will test three once-daily oral doses (30 mg, 60 mg, 90 mg) versus placebo with a primary endpoint of percent change in high-sensitivity C-reactive […] The post appeared first on <a href="